Investigational drug · Phase 2
GI-101A
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "GI-101A"
First trial start
2021
Aug 2, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GI-101A", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumor
- Metastatic Solid Tumor
- Cervical Cancer
- Urothelial Carcinoma
- Clear Cell Renal Cell Cancer (ccRCC)
- Squamous Cell Non Small Cell Lung Cancer
Approved drugs for the same conditions: Small cell lung cancer · Bladder and urothelial cancer · Cervical cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "GI-101A" as an intervention, largest first.
- GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid TumorsPivotal-lookingRecruiting
GI Innovation, Inc.Industry
NCT04977453 · 317 participants (planned) · Start Aug 2, 2021 · Primary completion Jun 30, 2028
Drug: GI-101; Pembrolizumab (KEYTRUDA®) and 2 more · For: Advanced Solid Tumor; Metastatic Solid Tumor; Cervical Cancer and 3 more
Sites: New York, New York; Huntersville, North Carolina; Seoul, South Korea · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Anti-angiogenic and pro-apoptotic effects of a small-molecule JFD-WS in in vitro and breast cancer xenograft mouse models.
Rathinavelu A, Kanagasabai T, Dhandayuthapani S, et al. · Oncol Rep 2018
- Anti-cancer effects of F16: A novel vascular endothelial growth factor receptor-specific inhibitor.
Rathinavelu A, Alhazzani K, Dhandayuthapani S, et al. · Tumour Biol 2017
- Oncolytic vaccinia virus GLV-1h68 strain shows enhanced replication in human breast cancer stem-like cells in comparison to breast cancer cells.
Wang H, Chen NG, Minev BR, et al. · J Transl Med 2012
- Bromelain-induced apoptosis in GI-101A breast cancer cells.
Dhandayuthapani S, Perez HD, Paroulek A, et al. · J Med Food 2012
- Selection of brain metastasis-initiating breast cancer cells determined by growth on hard agar.
Guo L, Fan D, Zhang F, et al. · Am J Pathol 2011
- Vaccinia virus GLV-1h237 carrying a Walker A motif mutation of mouse Cdc6 protein enhances human breast tumor therapy in mouse xenografts.
Hofmann E, Grummt F, Szalay AA · Int J Oncol 2011
Also in development for Advanced Solid Tumor
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.